Home › Trials › NCT05904119

Combining Lomustine with Reirradiation for Glioblastoma Progression

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Phase 3 Interventional European Organisation for Research and Treatment of Cancer - EORTC · NCT05904119

This study is testing if adding a chemotherapy drug called lomustine to reirradiation can help people with glioblastoma live longer after their cancer has progressed.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment411 (estimated)
Ages18 Years and up
SexAll
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC Research network
Drugs / interventionschemotherapy, bevacizumab
Locations43 sites (Innsbruck and 42 other locations)
Trial IDNCT05904119 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of combining lomustine, a standard chemotherapy drug, with reirradiation in patients experiencing the first progression of glioblastoma after initial treatment. The study aims to determine if this combination leads to improved overall survival compared to lomustine alone. Patients eligible for the trial must have measurable disease and a confirmed diagnosis of glioblastoma, with treatment starting at least six months after prior radiotherapy. The trial is randomized and phase III, indicating a robust methodology to assess the treatment's efficacy.

Who should consider this trial

Good fit: Ideal candidates are patients with first progression of glioblastoma who have undergone prior standard chemoradiotherapy and meet specific eligibility criteria.

Not a fit: Patients with glioblastoma who have not had prior treatment or those with other types of brain tumors may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve survival rates for patients with recurrent glioblastoma.

How similar studies have performed: While the combination of chemotherapy and reirradiation is a common approach, the specific efficacy of this combination in glioblastoma is still being evaluated, making this study both relevant and necessary.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Before patient's enrolment, written informed consent must be given according to ICH/GCP, and national/local regulations.
* Patients with first progression or recurrent glioblastoma after standard chemoradiotherapy (any treatment other than use of nitroureas) having occurred at least 6 months after the end of prior radiotherapy
* Measurable disease according to RANO criteria with a maximum tumour diameter of 5 cm (local investigator assessment)
* In case of surgery for recurrence: fully recovered from surgery, confirmation of recurrence by histology, and patient fit for treatment as per local investigator assessment.
* Histologically proven diagnosis of glioblastoma, IDH wildtype per WHO 2021 classification and local assessment of tissue from diagnosis or recurrence
* Initial treatment of newly diagnosed glioblastoma by maximal safe resection and postsurgical concurrent conventionally fractionated or abbreviated (minimum 15 fractions) chemoradiotherapy with or without maintenance chemotherapy with temozolomide (patient must have received at least one dose)
* Stable or decreasing dose of steroids for 7 days prior to enrolment
* Age ≥ 18 years
* WHO Performance status of 0-2
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
* Patients of childbearing / reproductive potential must agree to use adequate birth control measures during the study treatment period and for at least 6 months after the last dose of study treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.
* Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
* Non-sterile males must use contraception during treatment and for 6 months after the last dose.
* Non-sterile males must avoid sperm donation for the duration of the study and for at least 6 months after the last dose of study treatment.

Exclusion Criteria:

* Any prior anticancer treatment for recurrent glioblastoma (except surgery)
* Significant reduction in thrombocyte and/or leukocyte counts as well as severe renal impairment according to investigator's opinion
* History or present acute leukaemia or any myeloid disease
* Known hypersensitivity to the active components or excipients of lomustine
* Known coeliac disease or wheat allergy
* Live attenuated vaccine in the 3 months prior to lomustine initiation
* Any serious or uncontrolled medical condition (e.g., infections, chronic alcoholism, drug addiction) or abnormality, in the judgment of the investigator that prohibits obtaining informed consent, safe participation and study completion
* Known contraindication to imaging tracer or any product of contrast media and Magnetic Resonance Imaging (MRI) contraindications
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the trial.

Where this trial is running

Innsbruck and 42 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions First Progression of GlioblastomaFirst progressionGlioblastomaPhase IIILomustineReirradiation
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.